Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice

Cancer Biology and Therapy

Volumn 14, Issue 3, 2013, Pages 230-236

  Nishikawa, Toshio ^a   Takaoka, Munenori ^a   Ohara, Toshiaki ^a   Tomono, Yasuko ^b   Hao, Huifang ^a,c   Bao, Xiaohong ^a,c   Fukazawa, Takuya ^a   Wang, Zhigang ^c   Sakurama, Kazufumi ^a   Fujiwara, Yasuhiro ^a   Motoki, Takayuki ^a   Shirakawa, Yasuhiro ^a   Yamatsuji, Tomoki ^a   Tanaka, Noriaki ^a   Fujiwara, Toshiyoshi ^a   Naomoto, Yoshio ^a,d  

^a OKAYAMA UNIVERSITY   (Japan)

^b Shigei Medical Research Institute and Hospital   (Japan)

^c INNER MONGOLIA UNIVERSITY   (China)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Esophageal cancer; Molecular targeted therapy; MTOR; Prolonged survival; Temsirolimus

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR GROWTH; UPREGULATION;

ESOPHAGEAL CANCER; MOLECULAR-TARGETED THERAPY; MTOR; PROLONGED SURVIVAL; TEMSIROLIMUS;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ESOPHAGEAL NEOPLASMS; HUMANS; MICE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874915753     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23294     Document Type: Article

References (30)

1. Horner MJ, Ries RAG, Krapcho M, Neyman N, Aminou R, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Available from URL: http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
2. Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer 2008; 123:1422-8; PMID:18546259; http://dx.doi.org/10.1002/ijc.23691.
3. Neuner G, Patel A, Suntharalingam M. Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res 2009; 3:57-65; PMID:19461907.
4. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369-85; PMID:16890793; http://dx.doi.org/10.1053/j. seminoncol.2006.04.003. (Pubitemid 44142736)
5. Settleman J, Kurie JM. Drugging the bad "AKTTOR" to overcome TKI-resistant lung cancer. Cancer Cell 2007; 12:6-8; PMID:17613432; http://dx.doi.org/10.1016/j.ccr.2007.06.010. (Pubitemid 47001788)
6. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9:962-72; PMID:18804418; http://dx.doi.org/10.1016/S1470- 2045(08)70206-7.
7. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009; 6:352-66; PMID:19483740; http://dx.doi.org/10.1038/nrclinonc.2009. 62.
8. Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; 6:707-15; PMID:21258250; http://dx.doi.org/10.1097/JTO. 0b013e31820a3a6b.
9. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103:253-62.
10. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45; PMID:15314020; http://dx.doi.org/10.1101/gad.1212704. (Pubitemid 39071573)
11. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009; 8:3831-7; PMID:19901542; http://dx.doi.org/10.4161/cc.8.23.10070.
12. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010; 7:209-19; PMID:20234352; http://dx.doi.org/10.1038/nrclinonc.2010. 21.
13. Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 2009; 36(Suppl 3):S26-36; PMID:19963097; http://dx.doi.org/10.1053/j.seminoncol.2009.10.013.
14. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-22; PMID:15955899; http://dx.doi.org/10.1200/JCO.2005.66. 130. (Pubitemid 46206985)
15. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, et al.; North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005; 23:357-61; PMID:16012795; http://dx.doi.org/10.1007/s10637-005- 1444-0. (Pubitemid 40980358)
16. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95:1148-54; PMID:17031397; http://dx.doi.org/10. 1038/sj.bjc.6603419. (Pubitemid 44660065)
17. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822-9; PMID:19581539; http://dx.doi.org/10.1200/JCO.2008. 20.7977.
18. Kobayashi M, Naomoto Y, Nobuhisa T, Okawa T, Takaoka M, Shirakawa Y, et al. Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation 2006; 74:235-43; PMID:16759289; http://dx.doi.org/10.1111/j.1432-0436.2006.00072.x. (Pubitemid 43801422)
19. Ohara T, Takaoka M, Sakurama K, Nagaishi K, Takeda H, Shirakawa Y, et al. The establishment of a new mouse model with orthotopic esophageal cancer showing the esophageal stricture. Cancer Lett 2010; 293:207-12; PMID:20153104; http://dx.doi.org/10.1016/j.canlet.2010.01.017.
20. Ohara T, Takaoka M, Toyooka S, Tomono Y, Nishikawa T, Shirakawa Y, et al. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells. Cancer Sci 2011; 102:1344-9; PMID:21521416; http://dx.doi.org/10.1111/j.1349-7006.2011.01967.x.
21. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8:851-64; PMID:18846101; http://dx.doi.org/10.1038/nrc2501.
22. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35; PMID:21157483; http://dx.doi.org/10.1038/nrm3025.
23. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18:77-82; PMID:16357568; http://dx.doi.org/10.1097/01.cco. 0000198021.99347.b9. (Pubitemid 43740454)
24. Boone J, Ten Kate FJ, Offerhaus GJ, van Diest PJ, Rinkes IH, van Hillegersberg R. mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? J Clin Pathol 2008; 61:909-13; PMID:18474542; http://dx.doi.org/10.1136/jcp.2008.055772.
25. Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett 2007; 253:236-48; PMID:17360108; http://dx.doi.org/10.1016/j.canlet.2007.01.026. (Pubitemid 47017539)
26. Le Tourneau C, Faivre S, Serova M, Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008; 99:1197-203; PMID:18797463; http://dx.doi.org/10.1038/sj.bjc.6604636.
27. Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009; 115:3618-30; PMID:19479976; http://dx.doi.org/10.1002/cncr.24409.
28. Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008; 68:2934-43; PMID:18413763; http://dx.doi.org/10.1158/0008-5472.CAN- 07-6487. (Pubitemid 351556294)
29. Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, et al. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin Cancer Res 2008; 14:4631-9; PMID:18628478; http://dx.doi.org/10.1158/1078-0432.CCR-07-4755.
30. Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, et al. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol Rep 2008; 20:1473-7; PMID:19020730.